<DOC>
	<DOC>NCT01065727</DOC>
	<brief_summary>Cost-effectiveness study of 2 disease-modifying therapies (natalizumab versus mitoxantrone followed by immunomodulator) in the management of aggressive remitting multiple sclerosis</brief_summary>
	<brief_title>Impact Study of 2 Therapeutic Strategy for Aggressive Remitting Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<mesh_term>Immunologic Factors</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Adjuvants, Immunologic</mesh_term>
	<criteria>Patients with remitting multiple sclerosis according to mac Donald criteria aggressive remitting multiple sclerosis according to following criteria: 2 or less disabling relapse during the 12 months before inclusion 1 or more EDSS between 2 and 5 aged less or equal to 40 years old for the women effective contraception patients less than 18 years old</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Reemitting aggressive multiple sclerosis</keyword>
</DOC>